It's in the genes! Human genetic diversity and the response to anthrax vaccines

Expert Review of Vaccines

Volumn 11, Issue 6, 2012, Pages 633-635

  Ingram, Rebecca ^a   Baillie, Les ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anthrax; Genetic variation; Host response; Vaccine

Indexed keywords

ANTHRAX VACCINE;

ANTHRAX; DRUG RESPONSE; GENETIC VARIABILITY; HUMAN; HUMAN GENETICS; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS IMMUNITY;

ANTHRAX; ANTHRAX VACCINES; GENETIC VARIATION; HUMANS; IMMUNITY;

EID: 84864944992     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.41     Document Type: Review

References (20)

1. 633-635 1 Baillie LW. Is new always better than old?: The development of human vaccines for anthrax. Hum. Vaccin. 5(12), 806-816 (2009).
2. Ermini L, Wilson IJ, Goodship TH, Sheerin NS. Complement polymorphisms: geographical distribution and relevance to disease. Immunobiology 217(2), 265-271 (2012).
3. Cooke GS, Hill AV. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet. 2(12), 967-977 (2001).
4. Ingram RJ, Chu KK, Metan G et al. An epitope of Bacillus anthracis protective antigen that is cryptic in rabbits may be immunodominant in humans. Infect. Immun. 78(5), 2353; author reply 2353-2353; 4 (2010).
5. Marano N, Plikaytis BD, Martin SW et al.; Anthrax Vaccine Research Program Working Group. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 300(13), 1532-1543 (2008).
6. Crowe SR, Garman L, Engler RJ et al. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine 29(20), 3670-3678 (2011).
7. Gelder CM, Lambkin R, Hart KW et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis. 185(1), 114-117 (2002).
8. Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 5(4), 417-427 (2004).
9. Davenport MP, Hill AV. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol. Med. Today 2(1), 38-45 (1996).
10. Ingram RJ, Metan G, Maillere B et al. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J. Immunol. 184(7), 3814-3821 (2010).
11. Baillie LW, Huwar TB, Moore S et al. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 28(41), 6740-6748 (2010).
12. De Groot AS, Martin W. From immunome to vaccine: epitope mapping and vaccine design tools. Novartis Found. Symp. 254, 57-72; discussion 72 (2003).
13. Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 11(16), 5900-5911 (2005).
14. Tang YW, Li H, Wu H, Shyr Y, Edwards KM. Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine J. Infect. Dis. 196(7), 1021-1025 (2007).
15. Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum. Genet. 130(4), 547-561 (2011).
16. Barber GN. Cytoplasmic DNA innate immune pathways. Immunol. Rev. 243(1), 99-108 (2011).
17. Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22(21-22), 2881-2886 (2004).
18. Martchenko M, Candille SI, Tang H, Cohen SN. Human genetic variation altering anthrax toxin sensitivity. Proc. Natl Acad. Sci. USA 109(8), 2972-2977 (2012).
19. Rosovitz MJ, Schuck P, Varughese M et al. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278(33), 30936-30944 (2003).
20. Pomerantsev AP, Staritsin NA, Mockov YuV Marinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 15(17-18), 1846-1850 (1997).